A Randomized, Open-Label, Multicenter, Phase II Study Comparing the Effects on Proliferation and the Efficacy and Tolerability of Fulvestrant (FASLODEX) 500 mg With Fulvestrant (FASLODEX) 250 mg When Given as Neoadjuvant Treatment in Postmenopausal Women With Estrogen Receptor Positive Breast Cancer (T2, 3, 4b, N0-3, M0)

Trial Profile

A Randomized, Open-Label, Multicenter, Phase II Study Comparing the Effects on Proliferation and the Efficacy and Tolerability of Fulvestrant (FASLODEX) 500 mg With Fulvestrant (FASLODEX) 250 mg When Given as Neoadjuvant Treatment in Postmenopausal Women With Estrogen Receptor Positive Breast Cancer (T2, 3, 4b, N0-3, M0)

Completed
Phase of Trial: Phase II

Latest Information Update: 01 Jan 2016

At a glance

  • Drugs Fulvestrant (Primary)
  • Indications Advanced breast cancer; Early breast cancer; Menopause
  • Focus Adverse reactions; Biomarker; Pharmacodynamics; Pharmacokinetics; Therapeutic Use
  • Acronyms NEWEST
  • Most Recent Events

    • 01 Jan 2016 Results of a biomarker study in patients from this trial (n=30) and another pahse II trial (n=2) published in the International Journal of Cancer.
    • 24 Mar 2010 Tolerabilty results were presented at the European Breast Cancer Conference (EBCC-2010).
    • 24 Sep 2009 Tolerability results were presented at the 15th European Cancer Conference and the 34th Congress of the European Society for Medical Oncology (ECCO-ESMO 2009).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top